drugset / Trial / NCT00840840

600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fed Conditions

NCT00840840

Phase 1 Completed 48 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to assess the bioequivalence between Amoxicillin/Clavulanate Potassium Oral Suspension 600/42.9 mg/5 mL and Augmentin ES-600 Oral Suspension, 600/42.9 mg/5 mL in healthy, male and female subjects, under fed conditions.

Timeline

Start
2002-08
Primary completion
2002-08
Completion
2002-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 600 mg Oral
Subject Clavulanate Unknown 42.9 mg Oral

Indications

No indication recorded.